Genmab's Experimental Cancer Drug Shows Encouraging Results in Endometrial Cancer Trial

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

An ADC is a targeted therapy that delivers a potent drug directly to cancer cells.

The company said the 100 mg/m2 dose achieved a 50.0% objective response rate (ORR), meaning a significant reduction in tumor size, including two complete responses (CR), where all signs of cancer disappeared.

The median duration of response (mDOR), the time patients continued to respond to treatment, was not reached.

According to Ira Winer, a study investigator, these results are encouraging for patients with limited treatment options.

Genmab plans further evaluation in a Phase 2 and a planned Phase 3 trial, aiming to address an unmet need in gynecologic cancers, as stated by Judith Klimovsky, Chief Development Officer.